March 6, 2018
The NHI price of Sandoz/Kyowa Hakko Kirin’s Rituxan (rituximab) biosimilar, which was launched just in January, will be slashed by 9.5% in April as it was dragged by the originator drug into the scope of products subject to special re-pricing...read more